Dr. Susan Windham-Bannister is an internationally recognized innovation expert. She was named by the Boston Globe as one of the “10 Most Influential Women in Biotech” (2013) and by Boston Magazine as one of the "50 Most Powerful Women in Boston" (2011). Dr. Windham-Bannister currently serves as Managing Partner of Biomedical Innovation Advisors LLC, which she founded with Dr. Harvey Lodish, co-founder of Genzyme and a founding member of the Whitehead Institute, MIT. She also serves as the President and CEO of Biomedical Growth Strategies, LLC. Both of these advisory firms leverage Dr. Windham-Bannister’s experience as the immediate past President and CEO of the Massachusetts Life Sciences Center (MLSC), a state-funded investment organization charged with administering the $1-billion Life Sciences fund proposed by Governor Deval Patrick in 2007 and signed into law in June 2008. The MLSC is the hub for all sectors of the Commonwealth’s life sciences community – biotechnology, pharmaceuticals, medical devices, medical diagnostics and bioinformatics.
During her tenure as the founding executive of the MLSC, Dr. Windham-Bannister was responsible for the overall implementation of the Life Sciences Initiative, including formulating the investment strategy for the $1B fund, staffing and managing the organization, and building national and international partnerships. The MLSC’s portfolio of investments is catalyzing innovation, accelerating the commercialization of promising treatments, and is widely credited with establishing Massachusetts as the global leader life sciences. Under Dr. Windham-Bannister’s leadership, the MLSC invested nearly $700 million of the fund, leveraged another $2 billion in matching investment capital and made life sciences the fastest job-producing sectors of the Massachusetts economy. In September 2013, the MLSC won a national competition as a model of “Excellence in Technology-Based Economic Development.”
Before assuming her role at the MLSC, Dr. Windham-Bannister was co-founder and Managing Partner of Abt Bio-Pharma Solutions (ABS), a boutique consulting firm serving life sciences companies. She led the firm’s Commercial Strategy Group, which formulated market access and competitive business strategies for global clients. In her 35-year consulting career, she has been instrumental in the successful launch of a number of well-known therapeutics, medical devices and novel biomarkers, and has supported a number of high-profile M&A’s. Her client base included early stage as well as Fortune 50 life sciences (Pfizer, Merck, Novartis, Roche,), technology (IBM, GE) and financial services companies (CIGNA, Prudential, The Hartford, CitiGroup).
Dr. Windham-Bannister has co-authored two books: Competitive Strategy for Health Care Organizations, and Medicaid and Other Experiments in State Health Policy. She also has written numerous articles on competition in today’s health care marketplace and is a frequent speaker at national and international life sciences conferences.
Dr. Windham-Bannister received a B.A. from Wellesley College, a Doctorate in Health Policy and Management from the Florence Heller School at Brandeis University, and a Doctor of Science from Worcester Polytechnic Institute (honoris causa). She completed her doctoral work at the Heller School under a fellowship from the Ford Foundation and was also a post-doctoral fellow at Harvard University’s John F. Kennedy School. Dr. Windham-Bannister also served as a Fellow in the Center for Science and Policy (CSAP) at Cambridge University, Cambridge, England.